Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Biofilm formation - what we can learn from recent developments

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pentraxin-3 level at admission is a strong predictor of short-term mortality in a community-based hospital setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Harmonized diagnostic criteria for Alzheimer's disease: recommendations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dynamic soft tissue changes in the orbit after a blowout fracture

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reliability and validity of The Danish pediatric voice handicap index

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Acquired complement C1 esterase inhibitor deficiency in a patient with a rare SERPING1 variant with unknown significance

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: It has long been suggested that angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (AT2s) have some degree of 'cross-reactivity' in causing angioedema. Therefore, caution has been advised when switching patients with ACEi-related angioedema to an AT2.

OBJECTIVES: To clarify whether AT2s can be used safely in patients with a history of angioedema during ACEi treatment and to estimate the incidence rate of angioedema in patients subsequently treated with other antihypertensive drugs (beta-adrenergic blockers, calcium channel blockers, thiazides and analogues) or no antihypertensives.

METHODS: This is a nationwide retrospective registry-based cohort study of the Danish population during the period 1994 to 2016, and it uses Danish health registries. Propensity score adjusted and conventional proportional hazards regression models have been employed.

RESULTS: A total of 1 106 024 ACEi users were identified. In total, 5 507 (0.5%) of these patients had experienced angioedema during ACEi treatment and were included in the study. The highest risk of angioedema recurrence was associated with continued ACEi use at an adjusted hazard ratio of 1.45 (95% CI, 1.19 to 1.78). An inverse association was found between AT2s and angioedema (adjusted hazard ratio, 0.39; 95% CI, 0.30 to 0.51) compared with other antihypertensives (adjusted hazard ratios, 0.77 to 0.97).

CONCLUSIONS: Compared with other antihypertensive drugs, AT2s do not increase the incidence of angioedema in patients with previous ACEi-related angioedema.

OriginalsprogEngelsk
TidsskriftJournal of Internal Medicine
Vol/bind285
Udgave nummer5
Sider (fra-til)553-561
Antal sider9
ISSN0954-6820
DOI
StatusUdgivet - 1 maj 2019

ID: 56612626